Tinzaparin did not improve survival in patients with colorectal cancer: BMJ
Canada: Extended duration of perioperative anticoagulation with tinzaparin did not impact the disease-free survival or overall survival in patients with colorectal cancer following surgery, says an article published in the British Medical Journal.
Tinzaparin, a low molecular weight heparin, has demonstrated antimetastatic properties in preclinical models by possibly preventing tumor cell invasion of the extracellular matrix, impeding immune-mediated destruction of tumor cells in the circulation, and preventing the neovascularization of micro-metastases due to an antiangiogenic effect.
Between October 25, 2011, and December 31, 2020, 12 hospitals in Quebec and Ontario, Canada, participated in this multicenter, open label, randomized controlled experiment. Participants 614 people (age 18) who had invasive adenocarcinoma of the colon or rectum that had been pathologically verified, showed no signs of metastatic illness, had hemoglobin concentrations below 8 g/dL, and were planned for surgical resection were eligible. When compared to in-patient postoperative thromboprophylaxis alone, extended duration thromboprophylaxis with daily subcutaneous tinzaparin at 4500 IU, starting at the decision to operate, lasts for 56 days. The main result was disease-free survival at three years, which was defined as survival without death, distant metastases, a second primary for the same cancer, a second primary for a different malignancy, or locoregional recurrence. Secondary results were five year overall survival, serious surgical bleeding problems, and venous thromboembolism. Intent-to-treat analysis was conducted on this population.
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.